Venetoclax + obinutuzumab (fixed duration)
Checked 2026-09-09
Untreated CLL, all fitness levels
One cycle
every 28 days × 12 · about 48 weeks in totalComponents
| Drug | Dose | Route | Days | Note |
|---|---|---|---|---|
Obinutuzumab Monoclonal antibody (anti-CD20, glycoengineered type II) | 100 mg day 1, 900 mg day 2, 1,000 mg days 8 and 15 (cycle 1); 1,000 mg day 1 cycles 2-6 | IV | D1, 2, 8, 15 | |
Venetoclax Small-molecule BCL-2 inhibitor | 20 → 50 → 100 → 200 → 400 mg weekly ramp-up from cycle 1 day 22, then 400 mg daily | Oral | D22-28 |
Cycles
12 (venetoclax cycles 1 day 22 to end of cycle 12; obinutuzumab cycles 1-6)
28-day cycle
Emetogenicity
Minimal (<10%)
G-CSF
Not routine
Notes
- Tumour lysis risk stratified by lymph node size and lymphocyte count; hospital ramp-up for high risk.
- Strong CYP3A inhibitors are contraindicated during ramp-up.
Used in
Trials
Products
Source
Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.